anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Olanzapine is indicated as an integral part of a total treatment program for pediatric patients with schizophrenia and bipolar disorder that may include other measures (psychological, educational, social) for patients with the disorder. Effectiveness and safety of olanzapine have not been established in pediatric patients less than 13 years of age. Atypical antipsychotics are not intended for use in the pediatric patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders. Appropriate educational placement is essential and psychosocial intervention is often helpful. The decision to prescribe atypical antipsychotic medication will depend upon the physician’s assessment of the chronicity and severity of the patient’s symptoms [see Indications and Usage ( 1.3)] .

Symbyax ® (olanzapine and fluoxetine hydrochloride) is a trademark of Eli Lilly company.
Compsns. for promoting protein synthesis and conserving nitrogen in an organism comprise (a) the alpha-hydroxy acid analogues of essential amino acids, (b) the alpha-keto acid analogues of essential amino acids, and opt. (c) essential amino acids themselves. The compsns. can be used to treat renal and hepatic disorders (e.g. uraemia, hyperammoniaemia and portal-systemic encephalopathy) and nutritional protein deficiency. The hydroxy and keto acids modify the basic m tabolic mechanisms: in the case of renal disorders, they promote amino acid synthesis while suppressing the accumulation of urea in the blood stream; in the case of hepatic disorders, they utilise the ammonia in the blood stream for protein synthesis, which corrects nutritional problems while reducing the toxic effects of the ammonia; in the case of protein deficiency, they reduce the amt. of protein reqd. by the organism by suppressing the excretion of nitrogen (e.g. as urea).
BACKGROUND: Previous studies have shown that sleep quality plays an essential role in primary headaches to varying degrees. However, it is unclear precisely whether gut microbiota plays a critical role in mediating changes in sleep quality and affecting primary headaches.
METHODS: We utilized Mendelian randomization (MR) to examine the causal relationships between sleep quality and primary headaches. The data encompass eight sleep traits (staying asleep during periods of anxiety, trouble falling asleep, daytime dozing, sleep apnea syndrome, oversleeping, undersleeping, snoring, and sleeplessness). The primary statistical method employed was inverse variance weighting. Eventually, we explored whether gut microbiota mediate the relationship between sleep quality and primary headaches.
RESULTS: Our study found that a genetic predisposition to poor sleep quality increases the risk of primary headaches. Two-step MR analysis revealed that the genus Coprococcus1 mediates the causal relationship between trouble falling asleep and cluster headaches, with a mediating effect of 23.6%. These findings could inform targeted interventions and treatments for primary headaches.
CONCLUSION: This study suggests that trouble falling asleep increases the incidence of cluster headaches mediated by gut microbiota. It highlights the crucial impact of sleep quality on primary headaches.
Patients with Ewing sarcoma/peripheral PNET receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
Golimumab 50 mg supplied in a Smartject administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied a prefilled syringe 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab.
SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
Once consent is obtained the subject will choose from available time slots. Each subject will come to the UIHC Department of Ophthalmology at designated times for approximately one hour on five different days, for a total time commitment of approximately 5 hours. Each subject will receive the same 4 artificial tear substitutes and saline, one different drop each day. One of the four tear substitutes (brands: Systane, Systane Ultra, Optive, and Refresh) will be tested on each of the days. One drop will be used each day and the protocol of each day will be the same, the only factor changing from day to day is the drop that is being evaluated. On each study day, the subject will have a pre-instillation measurement of their higher order aberrometry of each eye. One drop of the designated drop will be placed into each of the eyes. Subsequent aberrometry measurements of each eye will be taken at immediately post-instillation, 5 minutes, 30 minutes and 60 minutes post instillation. The same protocol will be followed with a saline drop and thus each patient will act as a control.

There is no long-term follow-up.
Participants aged 60 or older, at high risk of falls, with Short Physical Performance Battery (SPPB) scores between 7 and 11, and without significant cognitive or vision impairment, were recruited for a non-randomized, two-arm study. They were evaluated at baseline and the third month. The intervention group (IG) underwent Steady Feet and CGH's standard care for fall prevention, while the control group (CG) received CGH's standard care for fall prevention. Feasibility was assessed across Bowen's domains, including acceptability, demand, implementation, practicality, adaptation, and limited efficacy. Measurements included SPPB, Timed Up and Go, the 6-minute walk test, the Four-Square Step Test, the CONFbal scale, and a satisfaction survey administered to IG participants. Between-groups statistical analyses will be performed.
All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-Nb-1 PET/CT scans (At the investigator's discretion, a total of no more than 0.5 mg of non-radiolabeled precursor may be considered for injection. To reduce liver and bone marrow uptake). After resting for 40 minutes or 1 hour, participants underwent United Imaging Healthcare total-body PET/CT for whole body scans or a Siemens Biograph m-CT flow PET/CT from the top of the head to the upper third of the thighs.
Novel sulphoxide cpds. of formula: R1-SO-CH2CH2-NH-R2. (HX)n (I) where R1 is benzyl, methyl, 2-hydroxyethyl, 2,3-dihydroxypropyl, alkyl or a gp. -CH2CH(OR3)2 where R3 is 1-3C alkyl, n is either O, in which case R2 is CONH2, or 1 in which case R2 is H and HX is an (in)org. acid. Compsns. for treating greasy hair or skin contains (I) in a suitable vehicle. It may be applied directly to the skin or hair or by administering the compsn. orally. Previous cysteame derivs. proposed for the above treatment have either had the disadvantage of a bad odour or of causing irritation to the skin. The above cpds. are both very effective and do not have these disadvantages.
Subjects will take DelanzoTMDR 60 mg Capsule, manufactured by SAMI Pharmaceuticals (Pvt.) Ltd. after at least 10 hours' fast, with 240 mL of ambient temperature water at their scheduled dosing time-point.
Neutrophil binding to vascular P- and E-selectin is the rate-limiting step in the recruitment of immune cells to sites of inflammation. Many diseases, including sickle cell anemia, post-myocardial infarction reperfusion injury, and acute respiratory distress syndrome are characterized by dysregulated inflammation. We have recently reported sialyl Lewisx analogues as potent antagonists of P- and E-selectin and demonstrated their in vivo immunosuppressive activity. A key component of these molecules is a tartrate diester that serves as an acyclic tether to orient the fucoside and the galactoside moiety in the required gauche conformation for optimal binding. The next stage of our study involved attaching an extended carbon chain onto one of the esters. This chain could be utilized to tether other pharmacophores, lipids, and contrast agents in the context of enhancing pharmacological applications through the sialyl Lewisx / receptor-mediated mechanism. Herein, we report our preliminary studies to generate a small library of tartrate based sialyl Lewisx analogues bearing extended carbon chains. Anionic charged chemical entities are attached to take advantage of proximal charged amino acids in the carbohydrate recognition domain of the selectin receptors. Starting with a common azido intermediate, synthesized using copper-catalyzed Huisgen 1,3-dipolar cycloadditions, these molecules demonstrate E- and P-selectin binding properties.
PURPOSE:To provide an in-organism heat generating substance which is safe even if it is embedded in a body for a long time and has extremely excellent affinity with surrounding organism tissue and selectively and high-efficiently heats an affected part containing the deep part of a body by a method wherein ferrite particles wrapped with an organism active inorganic layer and having ferromagnetism are used. CONSTITUTION:Mixture powder containing at least 90wt.% or more a composition consisting of 20-90wt.% ferrite particles, e.g. magnetite, lithium ferrite, magnesium ferrite, having ferromagnetism, and 80-10wt.% wt% crystal particles, e.g., beta-3CsO.P2O5, having organism activity, is sintered. A substance to be induction-heated can be utilized in a form of pulverized powder or a molded product, or fibrous shape. According to the form, by an intravenous injection, a hypodermic injection, oral administration, or embodiment operation, the substance is conveyed to an affected part formed by cancerous cells, being a body to be cured. Thereafter, by placing the substance in an AC magnetic field togetherwith the effected part, ferromegnetic substance ferrite particles can generate heat due to a magnetic hysteresis loss to heat the affected part for curing.
Centipede analgesic polypeptide PvTx, and encoding gene and application thereof, and relates to the technical field of biomedicine. The centipede analgesic polypeptide PvTx consists of an amino acid sequence in SEQ ID NO. 1. The coding centipede analgesic polypeptide PvTx gene sequence is shown in SEQ ID NO. 2. Use of centipede analgesic polypeptide PvTx as a TRPV1 channel agonist mediated TRPV1 desensitization response drug. The centipede analgesic polypeptide PvTx can generate analgesic activity by activating TRPV1 to mediate inactivation of a TRPV1 thermal activation pathway, and is used for preparing analgesic drugs.
The present invention is directed to compositions comprising 1-(β-D-ribofuranosyl)-1H-1,2,4-triazole compounds and either endogenous or exogenous neurotrophic factors. Methods of using such compounds and compositions are also provided. In one aspect, the invention provides methods of using invention compositions and compounds to enhance neurite outgrowth, neuronal survival and neuronal proliferation in mammalian cells. In a preferred embodiment, a 1-(β-D-ribofuranosyl)1H-1,2,4-triazole compound is infused directly to a desired situs. In a more preferred embodiment the 1-(β-D-ribofuranosyl)-1,2,4-triazole compound is administered orally. In another aspect, the invention provides methods of treating a neurological disease in a mammal subject. In a further aspect, the invention provides methods of treating neuronal trauma in a mammal subject.
Epogen from multiple-dose vials contains benzyl alcohol and is contraindicated for use in neonates, infants, pregnant women, and lactating women [see Contraindications (4)]. In addition, do not mix Epogen with bacteriostatic saline (which also contains benzyl alcohol) when administering Epogen to these patient populations [see Dosage and Administration (2)].

Serious and fatal reactions including “gasping syndrome” can occur in neonates and infants treated with benzyl alcohol-preserved drugs, including Epogen multiple-dose vials. The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. There is a potential for similar risks to fetuses and infants exposed to benzyl alcohol in utero or in breast-fed milk, respectively. Epogen multiple-dose vials contain 11 mg of benzyl alcohol per mL. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known [see Use in Specific Populations (8.1, 8.2, and 8.4)].
NEW MATERIAL:The stable clathrate compound of carmofur and beta-cyclodextrin, obtained by adding an organic acid to a beta-cyclodextrin mixture containing carmofur as an active component. USE:Remedy for malignant tumor having pyrimidine metabolism antagonistic activity. Effective to gastric cancer, colonic cancer, mammary cancer, etc. PREPARATION:The titled clathrate compound can be prepared by adding a small amount of an organic acid (e.g. tartaric acid, malic acid, maleic acid, citric acid, their mixture, etc.) in the preparation of the clathrate compound of carmofur and beta-cyclodextrin. The weight ratios of carmofur, beta-cyclodextrin and the acid are preferably 1:4.4:(0.5-2).
The invention belongs to the technical field of biological diagnosis. The invention discloses application of CCDC25A in preparing a canine lung cancer targeted therapeutic drug and a diagnostic reagent. The invention also discloses a drug for targeted treatment of canine lung cancer, which comprises a bleomycin-coupled monoclonal antibody against CCDC25A. The invention also discloses a gene detection kit for evaluating the treatment effect of the canine lung cancer targeted drug, which comprises a reagent for detecting the expression level of CCDC25A. The invention provides application of a reagent for detecting CCDC25A in preparing a product for diagnosing canine lung cancer. The application comprises the kit for diagnosing the canine lung cancer and the preparation of the pharmaceutical composition for treating the canine lung cancer. The kit can be used as one of means for diagnosing the canine lung cancer, and is one of indexes for evaluating the effect of the canine lung cancer on CCDC25A targeted therapy. The pharmaceutical composition has a good inhibition effect on canine lung cancer and has important reference significance in canine lung cancer treatment.
The duration of action of nalmefene hydrochloride injection is as long as most opioid analgesics. The apparent duration of action of nalmefene hydrochloride injection will vary, however, depending on the half-life and plasma concentration of the narcotic being reversed, the presence or absence of other drugs affecting the brain or muscles of respiration, and the dose of nalmefene hydrochloride injection administered. Partially reversing doses of nalmefene hydrochloride injection (1 mcg/kg) lose their effect as the drug is redistributed through the body, and the effects of these low doses may not last more than 30 to 60 minutes in the presence of persistent opioid effects. Fully reversing doses (1 mg/70 kg) have been shown to last many hours in both experimental and clinical studies, but may complicate the management of patients who are in pain, at high cardiovascular risk, or who are physically dependent on opioids.

The recommended doses represent a compromise between a desirable controlled reversal and the need for prompt response and adequate duration of action. Using higher dosages or shorter intervals between incremental doses is likely to increase the incidence and severity of symptoms related to acute withdrawal such as nausea, vomiting, elevated blood pressure, and anxiety.
The experimental treatment will contain an avocado. Avocados will be consumed daily for 4 weeks.
(450 mg) 

A single-dose, two-way crossover study was conducted in sixteen healthy male volunteers under fasting conditions with one 450 mg tablet being administered at 7 a.m. with a 6 oz. glass of water. No food or liquid (other than water) was allowed for 4 hours after which a standard lunch was served. Mean peak theophylline serum levels (Cmax) was 6.69 mcg/mL and mean time of peak serum concentration (Tmax) was 8.31 hours. 

(300 mg) 

A single-dose crossover study was conducted in twelve healthy male volunteers to compare pharmacokinetic parameters when theophylline extended-release tablets were administered with and without food. Subjects were fasted overnight and received a single 300 mg tablet early the following morning. 

When dosing was done under fed conditions, the subjects received a standard breakfast consisting of 2 fried eggs, 2 strips of bacon, 4 oz. hash brown potatoes, 1 slice of toast with a pat of butter, and 8 oz. whole milk 15 minutes pre-dosing. No food was allowed for five hours post-dosing, then a standard lunch was served; at ten hours post-dosing a standard supper was served. Mean peak theophylline serum levels for the two treatments were 3.7 mcg/mL (fasting) and 4.4 mcg/mL (with food). The time of peak serum level varied from subject to subject, occurring from 4 to 14 hours after dosing. However, 92% of the subjects had serum levels at least 75% of the maximum value at 4 to 8 hours after dosing, during each phase. 

Thus, blood samples taken 4 to 8 hours post-dosing should reference the peak serum level for most patients. The mean Tmax was 6.2 hours (fasting) and 8.7 hours (with food). The respective AUC (0-inf.) for these treatments were 73.3 mcg x hr/mL and 82.2 mcg x hr/mL, respectively.
The present invention relates to the treatment of cancer and particularly the neuroblastoma. The inventors focused for many years on immunotherapeutic strategies targeting the O-acetylated form of GD2 (OAcGD2), which they believed could address the critical neuropathic pain side effects associated with anti-GD2 mAb infusions. They reported previously that mAb 8B6 targeting OAcGD2 displays antitumor activity in NB tumor models, with induction of ADCC similarly to anti-GD2 mAbs. Based on these findings, the inventors interrogated here whether 13-cis-RA and more generally acid retinoic, may augment the anti-NB efficiency of mAb 8B6 therapy. They found a cooperative interaction of 13-cis-RA and mAb 8B6 treatment in inhibiting the NB growth in vivo. However, this combination regimen also coordinates PD-1/PD-L1 upregulation, which hinders a long-term activation of NK cells and allows tumor cell to relapse. Importantly this counter therapeutic effect can be leveraged with PD1 blockade to improve the therapeutic response of the mAb 8B6 + 13-cis-RA regimen. Thus, the present invention relates to a combination of retinoic acid, an anti-O-acetylated disialoganglioside (OAcGD2) compound and an anti-PD1/PD-L1 compound for use in the treatment of a cancer in a subject in need thereof.
Roberts syndrome (RBS) is an autosomal recessive disorder with profound growth deficiency and limb reduction caused by ESCO2 loss-of-function variants. Here, we elucidate the pathogenesis of limb reduction in an Esco2fl/fl;Prrx1-CreTg/0 mouse model using bulk- and single-cell-RNA-seq and gene co-expression network analyses during embryogenesis. Our results reveal morphological and vascular defects culminating in hemorrhage of mutant limbs at E12.5. Underlying this abnormal developmental progression is a pre-apoptotic, mesenchymal cell population specific to mutant limb buds enriched for p53-related signaling beginning at E9.5. We then characterize these p53-related processes of cell cycle arrest, DNA damage, cell death, and the inflammatory leukotriene signaling pathway in vivo. In utero treatment with pifithrin-α, a p53 inhibitor, rescued the hemorrhage in mutant limbs. Lastly, significant enrichments were identified among genes associated with RBS, thalidomide embryopathy, and other genetic limb reduction disorders, suggesting a common vascular etiology among these conditions.
Males and females with a paternal family history of alcoholism have a high risk for developing alcoholism. These individuals have been shown to have decreased dysphoric responses to alcohol self-administration that may promote the excessive use of alcohol. Ethanol has been shown to be an antagonist at the N-methyl-D-aspartate (NMDA) glutamate receptor. We have recently shown that sober alcoholics have decreased dysphoric response to the NMDA antagonist, ketamine. We propose to test the hypothesis that this characteristic exists as a vulnerability factor in those individuals susceptible to develop alcoholism. Specifically, the objective is to determine whether individuals with a family history positive (FHP) for alcoholism will experience less dysphoric, anxiogenic, and psychotogenic effects to alcohol infusion when compared to family history negative (FHN) control subjects.

Male and female subjects, FHP (biological father and one other first degree relative) between the ages of 21-30, and matched controls (FHN) will complete 3 test days in a randomized balanced order under double-blind conditions. Test days will involve administration of placebo or one of two ethanol doses (target BrAc=40mg%, or target BrAc=100mg%) intravenously for 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for over 60 minutes. Outcome measures include the Positive and Negative Symptom Scale, visual analog scales of mood state, (i.e. anxiety) and the Clinician-Administered Dissociative States Scale (CADSS) to measure perceptual responses to alcohol. Secondary measures include visual analog scales for high, similarity to ethanol, Mini Mental Status Examination (MMSE), Placement of electrodes, Biphasic Alcohol Effects Scale, Hopkins Verbal Learning, and number of drinks scale, aspects of craving for alcohol and tests of cognitive impairment.
Toothpaste and other dentifrices formulated to include a volume increasing agent (density reducing agent) in order to significantly increase the volume of the toothpaste at the time it is dispensed onto a toothbrush. The inventive dental compositions preferably include a substantial quantity of entrained air or other gas in order to reduce the density, and hence the weight, of toothpaste actually placed within a person's mouth. The result is a reduction in the amount of active ingredients introduced into a person's mouth that might be ingested. The entrained air or other gas can also increase the availability of the active ingredient since the foamed composition increases the dispersibility of the active ingredients within saliva. The net effect is that a person decreases the actual amount of toothpaste without decreasing the volume, or visual amount, of toothpaste dispensed on the toothbrush. The density-reduction effect can be augmented using a low density filler in addition to, or instead of, entrained gas. The inventive dentifrices might be pre-foamed with a storage container or formulated to foam in situ when dispensed from the storage container.